Skip to main content
Clinical Trials/NL-OMON33662
NL-OMON33662
Recruiting
N/A

Improvement of ischemia and myocardial blood flow in patients with ischemic cardiomyopathy after treatment with Electric Shock Wave Therapy using CMR - Electric Shock Wave Therapy

Vrije Universiteit Medisch Centrum0 sites8 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart failure
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
8
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Patient is male or female 18 years or older.
  • \* Patient is diagnosed with ischemic cardiomyopathy. I.e. a significantly impaired left ventriculair dysfunction (left ventricular ejection fraction \* 35 to 40 percent) that results from coronary artery disease based on a coronary angiogram.
  • \* Patient has documented myocardial segments with reversible ischemia and or hibernation.
  • \* Patient is classified as NYHA class II\-IV.
  • \* Patient should be on a stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment.
  • \* Patients where angioplasty and bypass are not indicated because of anatomical or procedural reasons or frequent reocclusion / restenosis following traditional revascularization.
  • \* Patient has refused to undergo another angioplasty or CABG.

Exclusion Criteria

  • \* Patient has chronic lung disease including emphysema and pulmonary fibrosis.
  • \* Patient has active endocarditis, myocarditis or pericarditis.
  • \* Patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization.
  • \* Patients who are unwilling or unable to cooperate with study procedure.
  • \* Patients with renal dysfunction with eGFR\<30 ml/min
  • \* Patients who are unwilling to quit smoking during the study procedure (including screening phase)
  • \* Patients who had MI less than 3 months prior to treatment
  • \* Patients who are diagnosed with a 3rd and 4th degree heart valve disease.
  • \* Patient with intraventricular thrombus
  • \* Patient is pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials